Memorial Sloan Kettering Basking Ridge
Basking Ridge, NJ
Accepting patients
Cabozantinib
A Phase II Study of Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- Tyrosine Kinase (TK) Inhibitor
- Phase 2
- Has results